Sign inJoin Free
DashboardSign out
Free Lesson Preview
Module 1: Lesson 1

Learn how ICH E6(R3) requires proportionate approaches that scale trial oversight and activities to the actual risks and importance of the data collected, focusing resources where they matter most.
Not every clinical trial is the same. A Phase I first-in-human study of a novel oncology compound carries risks fundamentally different from a Phase IV observational study of a well-established diabetes medication. A trial enrolling critically ill patients in intensive care units presents challenges distinct from one studying mild seasonal allergies in healthy volunteers. Yet for decades, the clinical research enterprise applied remarkably similar oversight approaches to all of them.
This one-size-fits-all mentality was never explicitly mandated. It emerged from a combination of institutional inertia, regulatory caution, and the understandable human tendency to apply familiar solutions to novel problems. If 100% source data verification worked for pivotal Phase III trials, the reasoning went, surely it would work everywhere. If weekly monitoring visits were appropriate for high-risk interventions, why not apply them universally?
The answer, which ICH E6(R3) now makes explicit, is that resources are finite and attention is limited. When everything receives the same level of scrutiny, nothing receives the level it actually needs. The site overwhelmed by monitoring activities for a low-risk trial may have its staff so burdened that they miss genuine problems. Meanwhile, the high-risk trial receiving the same template oversight may not get the intensive attention its complexity demands.
E6(R2), adopted in 2016, introduced risk-based monitoring concepts in its Addendum, marking the first formal ICH recognition that uniform oversight was neither required nor desirable. E6(R3) goes further, elevating proportionality from a monitoring concept to a core Principle that applies across all trial processes.
Principle 7 of ICH E6(R3) articulates this philosophy explicitly: the level of oversight and activity should match the actual risks and importance of what is being overseen.
By the end of this lesson, you will be able to:
Good Clinical Practice (GCP)
Full course · ICH E6(R3) Principles
Free Lesson Preview
Module 1: Lesson 1

Learn how ICH E6(R3) requires proportionate approaches that scale trial oversight and activities to the actual risks and importance of the data collected, focusing resources where they matter most.
Not every clinical trial is the same. A Phase I first-in-human study of a novel oncology compound carries risks fundamentally different from a Phase IV observational study of a well-established diabetes medication. A trial enrolling critically ill patients in intensive care units presents challenges distinct from one studying mild seasonal allergies in healthy volunteers. Yet for decades, the clinical research enterprise applied remarkably similar oversight approaches to all of them.
This one-size-fits-all mentality was never explicitly mandated. It emerged from a combination of institutional inertia, regulatory caution, and the understandable human tendency to apply familiar solutions to novel problems. If 100% source data verification worked for pivotal Phase III trials, the reasoning went, surely it would work everywhere. If weekly monitoring visits were appropriate for high-risk interventions, why not apply them universally?
The answer, which ICH E6(R3) now makes explicit, is that resources are finite and attention is limited. When everything receives the same level of scrutiny, nothing receives the level it actually needs. The site overwhelmed by monitoring activities for a low-risk trial may have its staff so burdened that they miss genuine problems. Meanwhile, the high-risk trial receiving the same template oversight may not get the intensive attention its complexity demands.
E6(R2), adopted in 2016, introduced risk-based monitoring concepts in its Addendum, marking the first formal ICH recognition that uniform oversight was neither required nor desirable. E6(R3) goes further, elevating proportionality from a monitoring concept to a core Principle that applies across all trial processes.
Principle 7 of ICH E6(R3) articulates this philosophy explicitly: the level of oversight and activity should match the actual risks and importance of what is being overseen.
By the end of this lesson, you will be able to:
Good Clinical Practice (GCP)
Full course · ICH E6(R3) Principles
You're already ahead of most
This lesson is part of a complete GCP certification track — 2 courses, quizzes, a final exam, and a certificate recognized by 18+ trial sponsors. It's entirely free.
Start your GCP certificateYou're already ahead of most
This lesson is part of a complete GCP certification track — 2 courses, quizzes, a final exam, and a certificate recognized by 18+ trial sponsors. It's entirely free.
Start your GCP certificate